Our mission
Our mission

Bring native bispecific therapeutics to patients

Our antibody development roots go deep

CD47 targeting
CD47 targeting

Safe and selective blockade of CD47 on tumors

Safe and selective blockade of CD47 on tumors

CD28 targeting

Safe and selective CD28 co-stimulation

Safe and selective blockade of CD47 on tumors

Who we are
Who we are

Our antibody development roots go deep

Our antibody development roots go deep

Our technology
Our technology, natural bispecific antibodies

Multispecific yet natural

κλ bodies

Looking into the future
Looking into the future

Beyond bispecific antibodies

Beyond bispecific antibodies

previous arrow
next arrow
  • CD28 targeting
  • How it works

CD28 costimulation

PD-L1-dependent CD28 costimulation

 

Step 1 – Tumor-specific T cells recognize their target via their T cell receptor (TCR)

T cells continuously scan a body’s cells in search of abnormalities, e.g., cancer cells. T cells use their surface receptor, T cell receptor (TCR), to bind peptides from degraded cell proteins complexed to major histocompatibility complex (MHC) molecules at the cell surface on cells. If the T cell’s TCR locates an MHC/peptide complex on a cancer cell, the binding triggers the so-called T cell activation “signal 1” (represented by a star in the figure below), which is the first step toward T cell activation.

PD-L1-dependent CD28 Costimulation

Step 2 – Tumor cells express PD-L1 to suppress T cell attack

Tumor cells can escape T cell surveillance by expressing PD-L1 at their surface. PD-L1 plays a major role in suppressing T cell responses by engaging the inhibitory checkpoint receptor PD-1 expressed on T cells. PD-1 exerts its activity by dampening T cell activation signals, including signal 1. Consequently, tumor-specific T cells are often unable to proficiently kill the cancer cells.

PD-L1-dependent CD28 Costimulation 1

Step 3 – By blocking PD-L1, the inhibitory signal preventing T cell activation can be limited

Thanks to its blocking anti-PD-L1 arm, NI-3201 can prevent tumor-expressed PD-L1 from interacting with PD-1 expressed by T cells. In the absence of PD-1-derived inhibitory signal, T cells can be effectively activated, thereby restoring their anti-tumor activity.

PD-L1-dependent CD28 Costimulation

Step 4 – Delivery of T cell costimulation further enhance T cell activation and response, leading to cancer cell killing

However, complete T cell activation necessitates a secondary signal (signal 2), typically facilitated by the CD28 receptor. Activation of CD28 not only initiates full T cell activation but also promotes their survival. Upon interaction with PD-L1 on target cells, NI-3201 can induce CD28 agonism, thereby culminating in thorough T cell activation and effective elimination of targeted tumor cells.

PD-L1-dependent CD28 Costimulation 1

Interested by this approach for your own projects? Partner with us

All drawings have been created by BIORENDER

Back

First Patient dosed with NILK-2401 in Phase I clinical trial

First-in-human trial of NILK-2401, a CEACAM5xCD47 bispecific κλ body


Read more

LinkedIn